Combined Immunodeficiency clinical trials at UCSF
1 in progress, 1 open to new patients
open to all eligible people
The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen.
San Francisco, California and other locations